Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoproliferative Disorders 4Immunoproliferative Disorders 4Hematologic Diseases 4Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Vascular Diseases 2Paraproteinemias 2Lymphoma 2Lymphatic Diseases 2Hemostatic Disorders 2Hemorrhagic Disorders 2Blood Coagulation Disorders 2Neoplasms, Plasma Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1

Interventions

tetulomab tetraxetan lu-177 2fludarabine 2dacetuzumab 2Lutetium 2Bendamustine Hydrochloride 2fludarabine phosphate 1ficlatuzumab 1denileukin diftitox 1Rituximab 1Lutetium-177 1Gemcitabine 1Erlotinib Hydrochloride 1Cyclophosphamide 1AP 1903 reagent 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Lymphatic Diseases × dacetuzumab × Clear all
NCT00103779 2014-12-18

A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma

Seagen Inc.

Phase 1 Completed
50 enrolled
Lymphoid

Hematologic Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Lymphoma, B-Cell

NCT00655837 2014-12-18

Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL

Seagen Inc.

Phase 1 Completed
33 enrolled
Lymphoid

Hematologic Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡